Harry Finch
Nessuna posizione attualmente
Profilo
Harry Finch is the founder and Founding Director of Kesmalea Therapeutics Ltd.
(founded in 2020).
He is currently a Director at Pulmagen Therapeutics (Inflammation) Ltd.
and Artios Pharma Ltd.
Dr. Finch has held former positions as a Chemistry Director at Glaxo Wellcome Plc and GSK Plc, a Research Director at RiboTargets Ltd., a Director & Executive Vice President at Pulmagen Therapeutics (Synergy) Ltd., a Chemistry Director at Glaxo Wellcome, Inc., a Non-Executive Director at C4X Discovery Ltd., a Director at Pulmagen Therapeutics (Holdings) Ltd.
and Pulmagen Therapeutics (Asthma) Ltd.
He was also an Independent Non-Executive Director at C4X Discovery Holdings Plc from 2014 to 2022.
Additionally, Dr. Finch worked as a Principal at Ciba-Geigy Corp.
and as a Senior Vice President-Therapeutics at Pulmagen Therapeutics LLP.
He obtained a doctorate degree from The University of Manchester.
Posizioni attive di Harry Finch
| Società | Posizione | Inizio |
|---|---|---|
| Pulmagen Therapeutics (Inflammation) Ltd. | Direttore/Membro del Consiglio | - |
Artios Pharma Ltd.
 Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom. | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Harry Finch
| Società | Posizione | Fine |
|---|---|---|
| C4X DISCOVERY HOLDINGS PLC | Direttore/Membro del Consiglio | 18/01/2022 |
| Glaxo Wellcome Plc | Corporate Officer/Principal | - |
| Pulmagen Therapeutics (Holdings) Ltd. | Direttore/Membro del Consiglio | - |
Pulmagen Therapeutics (Asthma) Ltd.
 Pulmagen Therapeutics (Asthma) Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Pulmagen Therapeutics LLP, Pulmagen Therapeutics (Asthma) Ltd. provides research and development services of natural sciences & engineering. The company is based in Slough, UK. | Direttore/Membro del Consiglio | - |
| Glaxo Wellcome, Inc. | Corporate Officer/Principal | - |
Formazione di Harry Finch
| The University of Manchester | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| GSK PLC | Health Technology |
| C4X DISCOVERY HOLDINGS PLC | Health Technology |
| Aziende private | 11 |
|---|---|
| Ciba-Geigy Corp. | Health Technology |
| Glaxo Wellcome Plc | Health Technology |
| RiboTargets Ltd. | Health Technology |
Pulmagen Therapeutics (Synergy) Ltd.
 Pulmagen Therapeutics (Synergy) Ltd. Miscellaneous Commercial ServicesCommercial Services Pulmagen Therapeutics (Synergy) Ltd. develops therapeutics for respiratory diseases. It engages in developing various internal proprietary programs in chronic obstructive pulmonary disease, asthma, and cystic fibrosis. The company was founded in August 2000 and is headquartered in Stevenage, the United Kingdom. | Commercial Services |
| Glaxo Wellcome, Inc. | Health Technology |
C4X Discovery Ltd.
 C4X Discovery Ltd. Pharmaceuticals: MajorHealth Technology C4X Discovery Ltd. engages in the discovery and development of medical drugs. It uses its NMR-based technology to solve the dynamic 3D structures of a broad range of biomolecules, including peptides, cofactors, oligonucleotides and carbohydrates. The company was founded by Andrew Almond and Charles Douglas Blundell in January 2008 and is headquartered in Manchester, the United Kingdom. | Health Technology |
Pulmagen Therapeutics LLP
 Pulmagen Therapeutics LLP Pharmaceuticals: MajorHealth Technology Pulmagen Therapeutics Ltd. manufactures and develops respiratory drugs. Its services include pulmagen respiratory product pipeline, pulmagen crth2 antagonist product pipeline, new generation bronchodilators-astrazeneca collaboration, theocort-inhaled corticosteroid re-sensitisation, inhaled ppar gamma agonists and chiesi collaboration-anti-inflammatory agents. The company was founded in February 2010 and is headquartered in Slough, the United Kingdom. | Health Technology |
| Pulmagen Therapeutics (Inflammation) Ltd. | |
| Pulmagen Therapeutics (Holdings) Ltd. | Commercial Services |
Pulmagen Therapeutics (Asthma) Ltd.
Pulmagen Therapeutics (Asthma) Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Pulmagen Therapeutics LLP, Pulmagen Therapeutics (Asthma) Ltd. provides research and development services of natural sciences & engineering. The company is based in Slough, UK. | Commercial Services |
Artios Pharma Ltd.
Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- Harry Finch
